Guggenheim Capital’s Global Blood Therapeutics, Inc. GBT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-28,129
| Closed | -$1.92M | – | 2046 |
|
|
2022
Q3 | $1.92M | Buy |
+28,129
| New | +$1.55M | 0.02% | 855 |
|
|
2021
Q4 | – | Sell |
-42,692
| Closed | -$1.09M | – | 2269 |
|
|
2021
Q3 | $1.09M | Buy |
42,692
+5,170
| +14% | +$152K | 0.01% | 1371 |
|
|
2021
Q2 | $1.31M | Buy |
37,522
+1,698
| +5% | +$66.3K | 0.01% | 1333 |
|
|
2021
Q1 | $1.46M | Sell |
35,824
-3,374
| -9% | -$155K | 0.01% | 1198 |
|
|
2020
Q4 | $1.7M | Sell |
39,198
-3,642
| -9% | -$180K | 0.01% | 1053 |
|
|
2020
Q3 | $2.36M | Sell |
42,840
-7,274
| -15% | -$462K | 0.02% | 817 |
|
|
2020
Q2 | $3.16M | Buy |
50,114
+11,481
| +30% | +$787K | 0.02% | 701 |
|
|
2020
Q1 | $1.97M | Sell |
38,633
-8,484
| -18% | -$568K | 0.02% | 795 |
|
|
2019
Q4 | $3.75M | Buy |
47,117
+278
| +0.6% | +$16.5K | 0.03% | 767 |
|
|
2019
Q3 | $2.27M | Buy |
46,839
+43
| +0.1% | +$2.24K | 0.02% | 958 |
|
|
2019
Q2 | $2.46M | Sell |
46,796
-11,309
| -19% | -$650K | 0.02% | 963 |
|
|
2019
Q1 | $3.08M | Sell |
58,105
-5,363
| -8% | -$264K | 0.03% | 878 |
|
|
2018
Q4 | $2.6M | Sell |
63,468
-2,609
| -4% | -$97.8K | 0.02% | 912 |
|
|
2018
Q3 | $2.51M | Buy |
66,077
+2,506
| +4% | +$111K | 0.02% | 1113 |
|
|
2018
Q2 | $2.87M | Buy |
63,571
+6,850
| +12% | +$312K | 0.02% | 1032 |
|
|
2018
Q1 | $2.74M | Sell |
56,721
-1,878
| -3% | -$105K | 0.01% | 1409 |
|
|
2017
Q4 | $2.31M | Sell |
58,599
-43,886
| -43% | -$1.64M | 0.01% | 1556 |
|
|
2017
Q3 | $3.18M | Buy |
102,485
+54,938
| +116% | +$1.54M | 0.01% | 1329 |
|
|
2017
Q2 | $1.3M | Buy |
+47,547
| New | +$1.41M | ﹤0.01% | 1913 |
|
Other funds holding GBT
Guggenheim Capital's GBT Position: Q4 2022 in Review
Guggenheim Capital sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2022, closing a stake of 28,129 shares — an estimated $1.92M sold.
Guggenheim Capital first reported a position in GBT in Q2 2017 and held it in 19 quarters. The position peaked at $3.75M in Q4 2019. 2 funds tracked by Wall St. Rank hold GBT as of Q4 2022.
- Guggenheim Capital reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
- Guggenheim Capital sold 28,129 Global Blood Therapeutics, Inc. shares in Q4 2022, an estimated $1.92M.
- Guggenheim Capital first reported a position in Global Blood Therapeutics, Inc. in Q2 2017 and held it in 19 quarters.
- Guggenheim Capital's Global Blood Therapeutics, Inc. position peaked at $3.75M in Q4 2019.
- 2 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2022.
Based on Guggenheim Capital's 13F filing for Q4 2022, filed 14 Feb 2023.